MNKD MannKind
Price Chart
Executive Summary
MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient population for the company's inhaled insulin product, a significant label expansion for a single-product biotech with a $1.1B market cap. The stock has a history of high volatility on news events.
Actionable Insight
This FDA approval for a pediatric indication transforms the commercial opportunity for Afrezza. Monitor next quarterly revenue and prescription trends for pediatric uptake. Historical performance shows MNKD can move violently (T+20 -29% on a bullish report previously), so position sizing should account for binary risk.
Key Facts
- FDA approved Afrezza for use in children and adolescents aged 6+ with diabetes
- This is a label expansion for MannKind's sole marketed product, Afrezza
- Company has a $1.1B market cap — early-stage biotech dynamics apply
Financial Impact
Afrezza is MannKind's only commercial product; approval in pediatric population (ages 6+) expands TAM meaningfully. No revenue or market size figures provided in press release.
Risk Factors
- Pediatric adoption of inhaled insulin may be slow due to safety perception or switching costs
- Single-product concentration risk remains — Afrezza still competes with injectable insulins and GLP-1 agonists
- No financial guidance or revenue contribution projections provided in this release
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303773 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
10d ago
|
Press Release
| $3.36 $3.52 | ▲ +4.76% | ▲ +4.36% | $3.66 (+8.93%) |
|
Jun 2, 2026
10d ago
|
8-K
| $3.43 $3.36 | ▼ −2.04% | ▼ −1.35% | $3.66 (+6.71%) |
|
May 29, 2026
14d ago
|
Press Release
| $3.77 $3.53 | ▼ −6.37% | ▼ −6.64% | $3.66 (−2.92%) |
|
May 29, 2026
14d ago
|
Press Release
| $3.77 $3.53 | ▼ −6.37% | ▼ −6.64% | $3.66 (−2.92%) |
|
May 28, 2026
15d ago
|
8-K
| $3.64 $3.77 | ▲ +3.57% | ▲ +3.33% | $3.66 (+0.55%) |
|
May 27, 2026
16d ago
|
Press Release
| $3.55 $3.64 | ▲ +2.54% | ▲ +1.98% | $3.66 (+3.10%) |
|
May 12, 2026
4w ago
|
Insider Cluster
| $3.28 $3.21 | ▼ −2.13% | ▼ −2.71% | $3.66 (+11.59%) |
|
May 6, 2026
5w ago
|
Press Release
| $3.55 $3.55 | · 0.00% | ▲ +0.83% | $3.66 (−3.10%) |
|
Apr 7, 2026
9w ago
|
DEFA14A
| $2.61 $2.56 | ▼ −1.92% | ▼ −2.49% | $3.66 (+40.23%) |
|
Feb 26, 2026
15w ago
|
8-K
| $3.24 $3.28 | ▲ +1.23% | ▲ +1.69% | $3.66 (+12.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access